These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23470476)

  • 21. Interview: Interview with Professor Malcolm Rowland.
    Rowland M
    Bioanalysis; 2010 Mar; 2(3):385-91. PubMed ID: 21083248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trials: from traditional to newer approaches part II.
    Macaluso M; Krams M; Preskorn SH
    J Psychiatr Pract; 2011 Jul; 17(4):277-84. PubMed ID: 21775829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Women in early-phase clinical drug trials: have things changed over the past 20 years?
    Fleisch J; Fleisch MC; Thürmann PA
    Clin Pharmacol Ther; 2005 Nov; 78(5):445-52. PubMed ID: 16321610
    [No Abstract]   [Full Text] [Related]  

  • 24. Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective.
    Tucker G; DeSilva B; Dressman J; Ito M; Kumamoto T; Mager D; Mahler HC; Maitland-van der Zee AH; Pauletti GM; Sasaki H; Shah V; Tang D; Ward M
    J Pharm Sci; 2016 Sep; 105(9):2489-2497. PubMed ID: 26886325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microdosing and drug development: past, present and future.
    Lappin G; Noveck R; Burt T
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory].
    Sawada Y; Yamada Y; Iga T
    Yakugaku Zasshi; 1997 Feb; 117(2):65-90. PubMed ID: 9084225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infusions Are the Optimal Dosing Method in Intravenous ADME Studies Rather Than Bolus Dosing.
    Barbour AM; Fossler MJ
    J Clin Pharmacol; 2018 Jan; 58(1):25-28. PubMed ID: 28815729
    [No Abstract]   [Full Text] [Related]  

  • 29. Eyes on New Product Development.
    Novack GD
    J Ocul Pharmacol Ther; 2017 Mar; 33(2):65. PubMed ID: 28099041
    [No Abstract]   [Full Text] [Related]  

  • 30. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 31. Innovations in phase 1 trial design: where do we go next?
    Collins JM
    Clin Cancer Res; 2000 Oct; 6(10):3801-2. PubMed ID: 11051221
    [No Abstract]   [Full Text] [Related]  

  • 32. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.
    Clas SD; Sanchez RI; Nofsinger R
    Drug Discov Today; 2014 Jan; 19(1):79-87. PubMed ID: 23993918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of endogenous roles of transporters for drug discovery: hitchhiking and metabolite-likeness.
    Kell DB
    Nat Rev Drug Discov; 2016 Feb; 15(2):143. PubMed ID: 26837595
    [No Abstract]   [Full Text] [Related]  

  • 34. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.
    Bosgra S; Vlaming ML; Vaes WH
    Clin Pharmacokinet; 2016 Jan; 55(1):1-15. PubMed ID: 26242381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs-The 4P Model.
    Norris DC; Sen S; Groisberg R; Subbiah V
    Mayo Clin Proc; 2020 Nov; 95(11):2566-2568. PubMed ID: 33153645
    [No Abstract]   [Full Text] [Related]  

  • 36. What is the definitive role of DMPK research for successful drug discovery and development? Until now and in the future.
    Hirabayashi H
    Drug Metab Pharmacokinet; 2014; 29(5):357-9. PubMed ID: 25345360
    [No Abstract]   [Full Text] [Related]  

  • 37. Microdosing in early lead discovery.
    Jekunen AP; Pauwels EK; Kairemo KJ
    Bioanalysis; 2010 Mar; 2(3):421-8. PubMed ID: 21083252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.
    Buöen C; Holm S; Thomsen MS
    J Clin Pharmacol; 2003 May; 43(5):470-6. PubMed ID: 12751268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?
    Horvath CJ; Milton MN
    Toxicol Pathol; 2009 Apr; 37(3):372-83. PubMed ID: 19244218
    [No Abstract]   [Full Text] [Related]  

  • 40. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.